Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Citing Articles

Influence of CAR T-cell therapy associated complications.

Umair M, Lai X, Xue Y, Yao H Front Oncol. 2025; 15:1494986.

PMID: 40052127 PMC: 11882432. DOI: 10.3389/fonc.2025.1494986.

Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients.

Evangelidis P, Tragiannidis K, Vyzantiadis A, Evangelidis N, Kalmoukos P, Vyzantiadis T Pathogens. 2025; 14(2).

PMID: 40005545 PMC: 11858289. DOI: 10.3390/pathogens14020170.

Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.

An J, Zhao J, Zou P, Zhang Y, Wei J, Tian W Cancer Med. 2024; 13(12):e7372.

PMID: 38923216 PMC: 11196838. DOI: 10.1002/cam4.7372.

Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study.

Camilli M, Viscovo M, Felici T, Maggio L, Ballacci F, Carella G Cardiooncology. 2024; 10(1):18.

PMID: 38532515 PMC: 10967131. DOI: 10.1186/s40959-024-00218-0.

Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond.

Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G Cancers (Basel). 2023; 15(13).

PMID: 37444456 PMC: 10340788. DOI: 10.3390/cancers15133346.

References

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

Mejstrikova E, Hrusak O, Borowitz M, Whitlock J, Brethon B, Trippett T . CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017; 7(12):659. PMC: 5802535. DOI: 10.1038/s41408-017-0023-x. View

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331. PMC: 5482103. DOI: 10.1182/blood-2017-02-769208. View

Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W . Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8):740-53. PMC: 5594743. DOI: 10.1056/NEJMoa1509277. View

Bonifant C, Jackson H, Brentjens R, Curran K . Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016; 3:16011. PMC: 5008265. DOI: 10.1038/mto.2016.11. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24(6):739-748. DOI: 10.1038/s41591-018-0036-4. View

Persons D, Baum C . Solving the problem of γ-retroviral vectors containing long terminal repeats. Mol Ther. 2011; 19(2):229-31. PMC: 3034864. DOI: 10.1038/mt.2010.305. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

10.

Kochenderfer J, Somerville R, Lu T, Yang J, Sherry R, Feldman S . Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017; 25(10):2245-2253. PMC: 5628864. DOI: 10.1016/j.ymthe.2017.07.004. View

11.

Fielding A, Richards S, Chopra R, Lazarus H, Litzow M, Buck G . Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2006; 109(3):944-50. DOI: 10.1182/blood-2006-05-018192. View

12.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

13.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

14.

Kebriaei P, Singh H, Huls M, Figliola M, Bassett R, Olivares S . Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016; 126(9):3363-76. PMC: 5004935. DOI: 10.1172/JCI86721. View

15.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

16.

Brudno J, Somerville R, Shi V, Rose J, Halverson D, Fowler D . Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016; 34(10):1112-21. PMC: 4872017. DOI: 10.1200/JCO.2015.64.5929. View

17.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

18.

Carpenter P, Englund J . How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127(23):2824-32. DOI: 10.1182/blood-2015-12-550475. View

19.

Giavridis T, van der Stegen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M . CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24(6):731-738. PMC: 6410714. DOI: 10.1038/s41591-018-0041-7. View

20.

Maus M, Nikiforow S . The Why, what, and How of the New FACT standards for immune effector cells. J Immunother Cancer. 2017; 5:36. PMC: 5394615. DOI: 10.1186/s40425-017-0239-0. View